3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
12
Leukemia
8
Leukemia, Myeloid, Acute
7
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Erythroblastic, Acute
3
Myeloproliferative Disorders
2
Myelodysplastic-Myeloproliferative Diseases
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Congenital Abnormalities
2
Skin Neoplasms
1
Oropharyngeal Neoplasms
1
Neutropenia
1
Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Childhood Acute Promyelocytic Leukemia With PML-RARA
1
Carcinoma, Squamous Cell
1
Carcinoma, Basal Cell
1
Breast Cancer Female
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
pirtobrutinib
5
Lenalidomide
4
Rituximab
3
Imatinib Mesylate
3
ruxolitinib
2
ponatinib
2
ibrutinib
2
Platelet Transfusion
2
Brentuximab Vedotin
2
Bortezomib
2
Bendamustine Hydrochloride
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
zanubrutinib
1
vosaroxin
1
venetoclax
1
nilotinib
1
idelalisib
1
bosutinib
1
acalabrutinib
1
Zoledronic Acid
1
Vorinostat
1
Vincristine
1
Tretinoin
1
Prednisone
1
Plasma Exchange
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Exercise
1
Doxorubicin
1
Dexamethasone
1
Denosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Diseases
×
Tretinoin
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled